Sartorius Stedim Biotech Stock
Stocks
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 198.10 EUR | +1.02% |
|
+5.99% | -5.67% |
| 09-08 | Sartorius Stedim Biotech : Barclays remains its Buy rating | ZD |
| 08-20 | UBS Upgrades Sartorius Stedim Biotech to Buy, Boosts PT | MT |
| Market Cap | 19.27B 22.1B 18.2B 16.53B 30.96B 2,121B 31.09B 218B 84.13B 1,078B 83.03B 81.19B 3,470B | P/E 2026 * |
50.5x | P/E 2027 * | 39.2x |
|---|---|---|---|---|---|
| Enterprise Value | 21.28B 24.41B 20.1B 18.25B 34.19B 2,342B 34.33B 241B 92.89B 1,191B 91.68B 89.65B 3,831B | EV / Sales 2026 * |
6.81x | EV / Sales 2027 * | 6.06x |
| Free-Float |
28.47% | Yield 2026 * |
0.42% | Yield 2027 * | 0.51% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| DIM | Real-time | |
CBOE
| DIMp | Real-time | |
|
OTC Markets
| SDMH.F | Delayed | |
|
Xetra
| 56S1 | Delayed | |
|
Börse Stuttgart
| 56S1 | Delayed | |
|
Tradegate
| 56S1 | Real-time | |
|
CBOE
| 0NK7 | Real-time | |
|
Boerse Muenchen
| 56S1 | Real-time | |
|
Deutsche Boerse AG
| 56S1 | Delayed | |
|
London S.E.
| 0RG8 | Delayed | |
|
Borsa Italiana
| 4DIM | End-of-day quote | |
|
Wiener Boerse
| DIM | End-of-day quote |
Last Transcript: Sartorius Stedim Biotech
| 1 day | +1.02% | ||
| 1 week | +5.99% | ||
| Current month | +1.07% | ||
| 1 month | +9.75% | ||
| 3 months | +19.70% | ||
| 6 months | +12.49% | ||
| Current year | -5.67% |
| 1 week | 182.4 |  | 198.8 |
| 1 month | 182.4 | | 203 |
| Current year | 150 | | 224 |
| 1 year | 150 | | 224 |
| 3 years | 139.1 | | 281 |
| 5 years | 139.1 | | 544 |
| 10 years | 50.13 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 51 | 2023-03-27 |
| Chief Tech/Sci/R&D Officer | 61 | 2011-09-07 | |
Petra Müller
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 2015-04-06 | |
Susan Dexter
BRD | Director/Board Member | 69 | 2015-04-06 |
Lothar Kappich
BRD | Director/Board Member | 69 | 2017-09-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/17/25 | Sell | Company | 750,000 | 0.7706% | ||
| 2/16/24 | Buy | Chief Executive Officer | 1,716,739 | 1.8624% | ||
| 3/2/22 | Sell | Company | 200,442 | 0.2174% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.02% | +5.99% | +7.20% | -19.54% | 21.91B | |
| +0.37% | +0.65% | -23.75% | +1.59% | 177B | |
| -0.69% | +1.29% | -3.62% | +11.27% | 119B | |
| -0.20% | -3.98% | +6.17% | +72.47% | 59.04B | |
| -0.24% | +1.74% | -3.94% | -31.61% | 49.41B | |
| -0.22% | -0.37% | +7.26% | +35.20% | 48.64B | |
| +1.61% | +7.61% | +17.91% | -6.24% | 33.18B | |
| -1.49% | -2.74% | - | - | 28.18B | |
| -1.17% | +4.64% | +42.09% | -8.18% | 25.8B | |
| -2.33% | -0.36% | -11.58% | +1.66% | 21.69B | |
| Average | -0.33% | +1.75% | +4.19% | +6.29% | 58.34B | |
| Weighted average by Cap. | -0.17% | +0.94% | -4.54% | +9.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.13B 3.59B 2.95B 2.68B 5.02B 344B 5.04B 35.37B 13.65B 175B 13.47B 13.17B 563B | 3.47B 3.98B 3.28B 2.97B 5.57B 382B 5.6B 39.23B 15.14B 194B 14.94B 14.61B 624B |
| Net income | 381M 437M 360M 327M 613M 41.97B 615M 4.31B 1.66B 21.34B 1.64B 1.61B 68.65B | 483M 554M 456M 414M 776M 53.16B 779M 5.46B 2.11B 27.03B 2.08B 2.04B 86.97B |
| Net Debt | 2.01B 2.3B 1.9B 1.72B 3.23B 221B 3.24B 22.71B 8.77B 112B 8.65B 8.46B 361B | 1.76B 2.01B 1.66B 1.51B 2.82B 193B 2.83B 19.86B 7.66B 98.21B 7.56B 7.39B 316B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-18 | €198.10 | +1.02% | 232,191 |
| 26-09-17 | €196.10 | +1.13% | 76,526 |
| 26-09-16 | €193.90 | +2.05% | 37,323 |
| 26-09-15 | €190.00 | +3.26% | 70,799 |
| 26-09-14 | €184.00 | -1.55% | 81,205 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
